Pharnext, an advanced clinical stage biopharmaceutical company specialized in
neurodegenerative diseases, announces the nomination of a new Board of Directors chaired by Michel de Rosen. Michel de Rosen – Chairman of Pharnext’s Board of Directors. President of Eutelsat Communications and member of ABB and Faurecia’s Boards of Directors. Michel de Rosen brings over 20 years of experience in the biotech and pharmaceutical industry.